help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on November 4, 2009
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-1679
This Article
Right arrow Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Wide, L.
Right arrow Articles by Hall, J. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wide, L.
Right arrow Articles by Hall, J. E.

Submitted on August 6, 2009
Accepted on October 14, 2009

The Common Genetic Variant of Luteinizing Hormone Has a Longer Serum Half-Life than the Wild Type in Heterozygous Women

Leif Wide*, Karin Eriksson, Patrick M. Sluss, and Janet E. Hall

Department of Medical Sciences, Clinical Chemistry (L.W., K.E.), University Hospital, SE 751 85 Uppsala, Sweden; and Reproductive Endocrine Unit, Department of Medicine (P.M.S., J.E.H.), Massachusetts General Hospital, Boston, Massachusetts 02114

* To whom correspondence should be addressed. E-mail: leif.wide{at}medsci.uu.se.

Context: The common genetic variant of human LH has two mutations and an extra N-linked oligosaccharide chain, a modification expected to affect the half-life in the circulation.

Objectives: Our objectives were to determine the half-lives of variant and wild-type forms of LH during GnRH receptor blockade in heterozygous women and to determine the time-related changes in isoform composition.

Design and Participants: Serum samples were obtained from three healthy women heterozygous for variant LH before and up to 20 h after administration of the NAL-GLU GnRH antagonist.

Main Outcome Measures: The half-lives were estimated by monoexponential decay. The number of sialic acid and sulfonated N-acetylgalactosamine residues per wild-type and variant LH molecule and the distribution of molecules with zero, one, two, or three sulfonated residues were measured.

Results: The variant LH had a half-life that was approximately 40% longer than the corresponding forms of wild-type LH (148 vs. 108 min; P < 0.001). Variant LH had more sialic acid residues per molecule than wild type (3.6 vs. 2.4; P < 0.05), whereas the number of sulfonated residues was similar (1.0 vs. 0.98). The decline in the variant LH during GnRH receptor blockade was associated with a decrease in sulfonated and an increase in sialic acid residues similar to that for in wild-type LH. Isoforms of either variant or wild-type LH with two to three sulfonate groups per molecule had the shortest half-life.

Conclusion: Variant LH remains longer in circulation than wild type during GnRH receptor blockade in heterozygous women, in accord with its higher content of sialic acid.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society